bluuebunny/crossref_metadata_2025_split huggingface dataset:
Observed Social Support Behaviors and Cancer-Related Cognitive Processing in Couples Coping with Head and Neck Cancer (HNC)
Authors: K Milbury , H Badr 
Published: March 2012

Abstract
Given the disfiguring and debilitating nature of HNC and its treatment, patients and their spouses are at risk of experiencing trauma symptoms including cognitive intrusion and avoidance which may exacerbate psychological distress. Even though the Social Cognitive Processing Model (SCPM) posits that social support facilitates adaptive cognitive processing, recent literature has pointed to harmful effects of received support. Most studies use self-report measures of perceived as opposed to actual received support focusing on the patient as the recipient of support. In reality, the support process is reciprocal and interdependent involving both receiving and providing support in both patients and spouses. Further, self-reports of cognitive processing are susceptible to self-presentation and defensive biases. The purpose of this research was to examine the association between actual observed support behaviors and cognitive intrusion and avoidance in 60 newly diagnosed HNC patients (87% male) and their spouses using a multi-method approach. As part of an ongoing longitudinal study, couples completed baseline questionnaires including an explicit measure of cognitive intrusion and avoidance (IES), completed a problem-solving discussion task in the laboratory immediately followed by an implicit assessment of cognitive intrusion (cancer Stroop task (CST)). We used the Social Support Interaction Coding System (SSICS) to code the video-recorded discussions. Dyadic analyses using multi-level modeling revealed that when patients and spouses received more (compared to less) positive support behaviors, they demonstrated slower reaction times (RT) on the CST (p &lt; .01) indicating greater cognitive intrusion. The results were similar using the self-report method (IES; p &lt; .05). No role differences (patients vs. spouses) were found. The current findings map on to recent literature suggesting that receiving support may be initially distressing in the acute phase of the traumatic event as it may elicit negative emotional responses, which are yet necessary to facilitate successful long-term adjustment. Thus, our next step in this ongoing longitudinal study is to examine long-term consequences of these findings as they will reveal clinical implications.
Epidemiological Risk Factors Associated with Inflammatory Breast Cancer Triple Negative Subtype
Authors: RL Atkinson , K Sexton , NT Ueno , S Krishnamurthy , W Woodward , R El-Zein , AM Brewster 
Published: March 2012

Abstract
Background: Inflammatory breast cancer (IBC) is rare and accounts for ∼1% of all invasive breast cancers. The 5-year survival rates are significantly lower than for other types of breast cancer, highlighting the significance of cancer prevention in IBC. A disproportionately higher percentage of IBC patients have triple-negative breast cancer (TNBC; ER−, PR− and Her2−) than patients with non-IBC. TNBCs are thought to arise from normal breast stem cells. Our preliminary data indicates that normal breast stem cells are enriched in adjacent normal tissues of patients with TN IBC. We hypothesize that parity and breastfeeding, risk factors that influence the normal stem cell compartment in the breast, will differ between TN IBC and non-TN IBC subtypes.
Methods: We identified 144 patients diagnosed with IBC in 1991–2011 at MD Anderson. Breast cancer risk factors including parity and breast-feeding were compared between patients with TN and non-TN IBC with chi square or Wilcoxon rank sum tests.
Results: The average age at diagnosis was 54 years; 83% of patients were non-Hispanic white; and 36% were TN IBC. We found that patients with TN IBC had significantly lower frequency (p = 0.02) and duration of breastfeeding (p = 0.02) compared with non-TN IBC patients. No differences were found in the frequency of other breast cancer risk factors.
Conclusion: The association between breastfeeding and TNBC indicates that stem cells that are retained in the absence of breastfeeding may be the cell of origin for TN IBC. These results highlight the importance of evaluating epidemiologic risk factors of IBC according to receptor subtype, which could lead to the identification of distinct etiologic pathways that could be targeted for prevention.
Benefits and Harms of Screening Mammography Frequency by Age and Comorbidity Score
Authors: D Braithwaite , W Zhu , R Hubbard , ES O'Meara , DL Miglioretti , B Geller , K Dittus , K Wernli , D Moore , K Kerlikowske 
Published: March 2012

Abstract
Background: There is uncertainty about the appropriate use of screening mammography in older women. We compared the benefits and harms of screening mammography frequency according to age and comorbidity scores.
Methods: We conducted analyses within a prospective cohort study of four mammography registries in the Breast Cancer Surveillance Consortium that had mammography data linked to Medicare claims information. Participants included 137,949 women aged 66–89 years without breast cancer and 2,993 women with breast cancer. We estimated odds of advanced (IIb, III, IV) stage, large tumor size (&gt;20 millimeters), and estrogen receptor (ER) negative tumors and cumulative probability of false-positive mammography after 10 years of screening by mammography frequency, age and comorbidity score as determined by the Charlson Comorbidity Index.
Results: Mammography biennially vs. annually for women aged 66–89 years does not increase risk of tumors with unfavorable characteristics regardless of women's comorbidity score. Cumulative probability of a false-positive result for annual and biennial screening of women aged 66–89 years with a comorbidity score of ≥1 was 48 (46.1, 49.9) and 29 (28.1, 29.9) respectively. False-positives were more common among annual screeners than among those screened biennially irrespective of women's comorbidity score.
Conclusion: Mammography annually vs. biennially does not have added benefit for women aged 66–89 years, even among those in good overall health as reflected by the lack of comorbidity. Risk of false-positive mammography is much higher with annual mammography.
Immune Responses Contribute to Depression, Fatigue, and Pain in Hematopoietic Stem Cell Transplant Recipients
Authors: E Costanzo , M Juckett , A Nelson , A Erdmann , P Rathouz , P Hematti , C Coe 
Published: March 2012

Abstract
Depression, fatigue, and pain are prevalent and distressing quality of life concerns for individuals recovering from hematopoietic stem cell transplantation (HSCT). Recent research in other cancer populations suggests inflammatory cytokines can activate central nervous system pathways, evoking adverse behavioral responses including depressed mood, fatigue, and pain. We hypothesized that inflammatory responses also contribute to these symptoms among HSCT recipients. Participants (24 allogeneic and 68 autologous transplant recipients) completed well-validated measures of depressive symptoms, fatigue, and pain prior to transplant and 30, 100, and 200 days post-transplant. Circulating proinflammatory (IL-6, TNFÎ±) and regulatory (IL-10) cytokines were measured by ELISA in peripheral blood plasma at the same time points. Subject-level fixed effects and mixed effects linear regression models were employed to examine relationships between cytokine levels and quality of life assessments. Results indicated that depression and fatigue were most severe 30 days post-transplant, with allogeneic recipients showing markedly slower improvement than autologous recipients at later assessments. Pain did not change significantly over time. Among individual patients, changes in IL-6 levels across the assessment points were associated with corresponding changes in depressive symptoms (t = 2.0, p = .048), fatigue (t = 2.7, p = .008), and pain (t = 2.0, p = .048), after adjusting for the effects of time since transplant. Similarly, participants with elevated IL-6 levels reported more severe depression (z = 2.9, p = .004), fatigue (z = 2.9, p = .004), and pain (z = 3.0 p = .003) compared to participants with low/normal IL-6 levels. All models adjusted for graft type and recipient's age. Similar relationships were seen for IL-10, while TNFÎ± was not significantly associated with symptoms. Results provide evidence for a novel biobehavioral pathway by which inflammatory processes secondary to treatment and/or treatment-related complications may contribute to depression, fatigue, and pain among HSCT recipients. Findings may assist health care providers in identifying patients at risk for this constellation of symptoms.
Race and Risk of Large Bowel Polyps in Younger and Older Patients
Authors: K Wallace , D Ahnen , C Burke , E Barry , R Bresalier , F Saibil , J Baron 
Published: March 2012

Abstract
African Americans (AA) have a higher incidence of colorectal cancer (CRC) compared to European Americans (EA). However, AA are consistently diagnosed with CRC at a younger age suggesting a possible biologic difference in neoplasms by race. Few studies have investigated racial differences in risk of adenomas, precursors to most colorectal cancer and, to our knowledge, none have investigated whether this risk differs by adenoma type or age. To address this gap, we analyzed data pooled from three placebo-controlled adenoma chemoprevention trials to explore racial differences in the risk of large bowel polyps among younger and older subjects. Eligible subjects had at least one documented adenoma and were followed until their next scheduled colonoscopy. Using generalized linear regression, we estimated risk ratios and 95% confidence intervals (CI) as measures of the association between race and risk for one or more adenomas, advanced lesions, or hyperplastic polyps (HP) after randomization adjusting for age, sex, follow-up time, and treatment assignment. We defined advanced lesions as adenomas with at least 25% villous component, high-grade dysplasia, or an estimated size of 1 ≥ centimeter. We also assessed the potential interaction between race and age on the risk of large bowel polyps. Of the 2683 subjects enrolled, 2605 completed one follow-up exam after randomization (193 AA, 2412 EA). Overall, our results suggested a racial difference in risk for adenomas among younger (&lt;50 years) but not among older (≥50 years) subjects (p-for interaction between age and race for any adenoma (p = 0.13) and for advanced adenoma (p = 0.04)). Younger AA, when compared to EA had a significantly higher risk of any adenoma (RR 1.73, 95% CI 1.00–3.00) and advanced lesions (RR 4.40, 95% CI 1.47–13.15) but no difference in risk of HP. Among older patients, using the same comparison, there was no racial difference in risk of adenomas (RR 1.06, 95% CI 0.91–1.25) or advanced lesions (RR 1.06, 95% CI 0.71–1.57)) but there was a significantly lower risk of HP (RR 0.64 (95% CI 0.47–0.88). Our findings suggest that older AA have a lower risk of HP; and AA under the age of 50 years of age are at increased risk of adenomas, especially advanced lesions.
Hepcidin Destabilizes Atherosclerotic Plaque Via Overactivating Macrophages After Erythrophagocytosis
Authors: Li Jing Jing , Meng Xiao , Si Hai Peng , Zhang Cheng , Lv Hui Xia , Zhao Yu Xia , Yang Jian Min , Dong Mei , Zhang Kai , Liu Su Xia , Zhao Xue Qiang , Gao Fei , Liu Xiao Ling , Cui Tai Xing , Zhang Yun 
Published: March 2012

Objective—
To explore a direct and causal relationship between vascular hepcidin and atherosclerotic plaque stability.

Methods and Results—

Accelerated atherosclerotic lesions were established by perivascular collar placement in apolipoprotein E–deficient (ApoE
−/−
) mice. Adenoviral overexpression of hepcidin in the carotid artery during plaque formation enhanced intraplaque macrophage infiltration and suppressed the contents of collagen and vascular smooth muscle cells, whereas hepcidin shRNA treatment exerts opposite effects. The overexpression or knockdown of hepcidin did not affect plaque lipid deposition but increased or decreased oxidized low-density lipoprotein (ox-LDL) levels within intraplaque macrophages. In cultured macrophages, ox-LDL not only increased reactive oxygen species formation, inflammatory cytokine production, and apoptosis but also upregulated hepcidin expression. However, hepcidin did not exaggerate the ox-LDL–induced activation of macrophages until an onset of erythrophagocytosis. Whereas hepcidin was critical for the upregulation of L-ferritin and H-ferritin in both ox-LDL–treated erythrophagocytosed macrophages and atherosclerotic plaques, the adding of iron chelators suppressed the intracellular lipid accumulation, reactive oxygen species formation, inflammatory cytokine expression, and apoptosis in erythrophagocytosed macrophages.

Conclusion—
Hepcidin promotes plaque destabilization partly by exaggerating inflammatory cytokine release, intracellular lipid accumulation, oxidative stress, and apoptosis in the macrophages with iron retention.
A Novel mRNA Binding Protein Complex Promotes Localized Plasminogen Activator Inhibitor-1 Accumulation at the Myoendothelial Junction
Authors: Heberlein Katherine R. , Han Jenny , Straub Adam C. , Best Angela K. , Kaun Christoph , Wojta Johann , Isakson Brant E. 
Published: March 2012

Objective—
Plasminogen activator inhibitor-1 (PAI-1) has previously been shown to be key to the formation of myoendothelial junctions (MEJs) in normal and pathological states (eg, obesity). We therefore sought to identify the mechanism whereby PAI-1 could be selectively accumulated at the MEJ.

Methods and Results—
We identified PAI-1 protein enrichment at the MEJ in obese mice and in response to tumor necrosis factor (TNF-α) with a vascular cell coculture. However, PAI-1 mRNA was also found at the MEJ and transfection with a PAI-1–GFP with TNF-α did not demonstrate trafficking of the protein to the MEJ. We therefore hypothesized the PAI-1 mRNA was being locally translated and identified serpine binding protein-1, which stabilizes PAI-1 mRNA, as being enriched in obese mice and after treatment with TNF-α, whereas Staufen, which degrades PAI-1 mRNA, was absent in obese mice and after TNF-α application. We identified nicotinamide phosphoribosyl transferase as a serpine binding protein-1 binding partner with a functional τ-like microtubule binding domain. Application of peptides against the microtubule binding domain significantly decreased the number of MEJs and the amount of PAI-1 at the MEJ.

Conclusion—
We conclude that PAI-1 can be locally translated at the MEJ as a result of a unique mRNA binding protein complex.
Incidence and Outcome of Surgical Procedures After Coronary Bare-Metal and Drug-Eluting Stent Implantation
Authors: Tokushige Akihiro , Shiomi Hiroki , Morimoto Takeshi , Furukawa Yutaka , Nakagawa Yoshihisa , Kadota Kazushige , Iwabuchi Masashi , Shizuta Satoshi , Tada Tomohisa , Tazaki Junichi , Kato Yoshihiro , Hayano Mamoru , Abe Mitsuru , Ehara Natsuhiko , Inada Tsukasa , Kaburagi Satoshi , Hamasaki Shuichi , Tei Chuwa , Nakashima Hitoshi , Ogawa Hisao , Tatami Ryozo , Suwa Satoru , Takizawa Akinori , Nohara Ryuji , Fujiwara Hisayoshi , Mitsudo Kazuaki , Nobuyoshi Masakiyo , Kita Toru , Kimura Takeshi 
Published: March 2012

Background—
There still remain safety concerns on surgical procedures after coronary drug-eluting stents (DES) implantation, and optimal management of perioperative antiplatelet therapy (APT) has not been yet established.

Methods and Results—

During 3-year follow-up of 12 207 patients (DES=6802 patients and bare-metal stent [BMS] only=5405 patients) who underwent coronary stent implantation in the CREDO-Kyoto registry cohort-2, surgical procedures were performed in 2398 patients (DES=1295 patients and BMS=1103 patients). Surgical procedures (early surgery in particular) were more frequently performed in the BMS group than in the DES group (4.4% versus 1.9% at 42-day and 23% versus 21% at 3-year, log-rank
P
=0.0007). Cumulative incidences of death/myocardial infarction (MI)/stent thrombosis (ST) and bleeding at 30 days after surgery were low, without differences between BMS and DES (3.5% versus 2.9%,
P
=0.4 and 3.2% versus 2.1%,
P
=0.2, respectively). The adjusted risks of DES use relative to BMS use for death/MI/ST and bleeding were not significant (hazard ratio: 1.63, 95% confidence interval: 0.93 to 2.87,
P
=0.09 and hazard ratio: 0.6, 95% confidence interval: 0.34 to 1.06,
P
=0.08, respectively). The risks of perioperative single- and no-APT relative to dual-APT for both death/MI/ST and bleeding were not significant; single-APT as compared with dual-APT tended to be associated with lower risk for death/MI/ST (hazard ratio: 0.4, 95% confidence interval: 0.13 to 1.01,
P
=0.053).

Conclusions—
Surgical procedures were commonly performed after coronary stent implantation, and the risk of ischemic and bleeding complications in surgical procedures was low. In patients selected to receive DES or BMS, there were no differences in outcomes. Perioperative administration of dual-APT was not associated with lower risk for ischemic events.
Comparison of 5-Year Clinical Outcomes Between Sirolimus-Versus Paclitaxel-Eluting Stent
Authors: Park Kyungil , Park Kyung Woo , Rha Seung-Woon , Bae Jang-Ho , Hur Seung-Ho , Park Jong-Seon , Yoon Jung-Han , Jang Yangsoo , Jeong Myung-Ho , Kim Hyo-Soo 
Published: March 2012

Background—
The paclitaxel-eluting stent (PES) and sirolimus-eluting stent (SES) are first-generation drug-eluting stents (DES) that have been the most widely used; however, it is unclear whether there are differences in the long-term safety and efficacy between the 2 stents. The long-term effectiveness of DES in unselected people with diabetes is also currently unclear. Moreover, the possibility of late catch-up is suggested in the DES population.

Methods and Results—

This study is an 8-center collaborative network analysis of all comers who received SES and PES. All patients who received SES and PES from February 2003 to October 2006 were enrolled. We analyzed 9315 patients (33.3% with diabetes) treated with SES or PES in the major 8 centers representing whole area of Korea. The primary end point was a major adverse cardiac event (MACE) composite of overall death, myocardial infarction, and target lesion revascularization. All analyses were performed using multivariable, adjusted models and propensity score-matching methods. Long-term MACE for 5 years were significantly lower in the SES than the PES group (13.3% versus 15.6%; hazard ratio, 0.82; 95% confidence interval, 0.71 to 0.96;
P
=0.01), which was mainly driven by the difference of MACE within the first year (hazard ratio, 0.73; 95% CI, 0.59 to 0.90;
P
=0.003), but the rate of MACE between 1 and 5 years in the landmark analysis was not different between the 2 stents (1.9 versus 2.0%/yr). In the subpopulation of people with diabetes, in contrast to the whole population, PES was comparable to SES in terms of any clinical outcome, both within the first year and from 1 to 5 years (MACE for 5 years, 20.3 versus 17.9%; MACE within the first year, 9.6 versus 8.2%; MACE 1 to 5 years, 2.9 versus 2.6%/yr).

Conclusions—
The PES was inferior to the SES in the clinical follow-up of more than 9000 patients' cohort for 5 years, which was mainly driven by the difference in the first year. In the subpopulation of people with diabetes that showed higher MACE than people without diabetes, however, PES was comparable to SES in any clinical outcome for 5 years. Although these 2 stents are not frequently used as before, the data would be useful to expect the long-term clinical course of the current DES.
Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension
Authors: Barzilay Joshua I. , Davis Barry R. , Pressel Sara L. , Cutler Jeffrey A. , Einhorn Paula T. , Black Henry R. , Cushman William C. , Ford Charles E. , Margolis Karen L. , Moloo Jamaluddin , Oparil Suzanne , Piller Linda B. , Simmons Debra L. , Sweeney Mary Ellen , Whelton Paul K. , Wong Nathan D. , Wright Jackson T. ,   for the ALLHAT Collaborative Research Group
Published: March 2012

Background—
Thiazide-type diuretics are associated with an increased incidence of diabetes compared with other antihypertensive medications. In this study, we determined the long-term cardiovascular disease (CVD) consequences of incident diuretic-associated diabetes compared with the effects of incident diabetes associated with calcium channel blocker and angiotensin-converting enzyme inhibitor use.

Methods and Results—

A total of 22 418 participants from the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) with baseline diabetes, incident diabetes (7.5% with chlorthalidone, 5.6% with amlodipine, and 4.3% with lisinopril), or no diabetes at 2 years of in-trial follow-up were followed for a mean total of 6.9 years (2.9 years in-trial and 4 additional years posttrial) through the use of national databases. The primary outcome was CVD mortality (death from coronary heart disease [CHD], stroke, heart failure, or other CVD). Among other outcomes were all-cause mortality, non-CVD mortality, and CHD (nonfatal myocardial infarction or fatal CHD). Participants on chlorthalidone with incident diabetes versus no diabetes had consistently lower, nonsignificant risk for CVD mortality (hazard ratio [HR], 1.04; 95% CI, 0.74–1.47), all-cause mortality (HR, 1.04; 95% CI, 0.82–1.30), and non-CVD mortality (HR, 1.05; 95% CI, 0.77–1.42) than participants on amlodipine or lisinopril with incident diabetes (HR range, 1.22–1.53). Participants with incident diabetes had elevated CHD risk compared with those with no diabetes (HR, 1.46; 95% CI, 1.09–1.96), but those on chlorthalidone had significantly lower risk than those on lisinopril (HR, 1.18 versus 2.57;
P
=0.04 for interaction).

Conclusions—
The findings suggest that thiazide-related incident diabetes has less adverse long-term CVD impact than incident diabetes that develops while on other antihypertensive medications.

Clinical Trial Registration—

URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT00000542.